Iparomlimab and Tuvonralimab (QL1706) for Intermediate Trophoblastic Tumors

Clinical trial NCT06941766 · RECRUITING

Trial details

NCT number: NCT06941766
Sponsor: Peking Union Medical College Hospital
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Intermediate Trophoblastic Tumor

Start date: 2025-04-15
Primary completion: 2027-04-16
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.